Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
NeuroVoices: Crystal Proud, MD, on Improving SMA Outcomes Through a Combination Approach
July 12th 2023The director of neurology and neuromuscular medicine at the Children’s Hospital of the King’s Daughters in Norfolk, Virginia, provided perspective on the phase 4 RESPOND study assessing nusinersen in individuals with SMA who already received gene therapy.
AI Model SCORE-AI Shows Clinical Utility in Reading Abnormal EEGs, Distinguishing Seizure Types
July 10th 2023Interrater agreement between SCORE-AI and human experts was notable, with almost perfect agreement for generalized epileptiform abnormalities and substantial agreement for focal epileptiform discharges, among other findings.
Burel Goodin, PhD, on Building Trust in Underserved Communities to Improve Clinical Trial Outcomes
July 5th 2023The professor of anesthesiology at Washington University in St. Louis discussed the importance of effectively communicating and reciprocating with underserved communities that are of research interest.
Increased Mortality Risk and Shorter Life Expectancy Associated With Sleeping Pills
July 3rd 2023Among sleeping pill nonusers, when compared with patients who got a medium amount of sleep, extremely short or long sleepers had approximately 30% higher risk of all-cause mortality and 3-5 years shorter life expectancy at age 30-50 years.
Episode 92: Highlights From the 2023 CMSC, SLEEP, AHS, and ATMRD Annual Meetings
June 30th 2023Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Amit Bar-Or, MD; Gavin Giovannoni, MBBCh, PhD; Dayna Johnson, PhD, MPH, MSW, MS; John Winkelman, MD, PhD; Laxman Bahroo, DO; Ling Wan-Albert, OTD, OTR/L; Sara Pavitt, MD; and Ali Ezzati, MD. [LISTEN TIME: 28 minutes]
Gaining a Better Understanding of Idiopathic Hypersomnia, Uses of Low-Sodium Oxybate
June 27th 2023Marisa Whalen, PharmD, associate director of Medical Affairs at Jazz Pharmaceuticals, discussed presentations at SLEEP 2023 on the real-world burdens of idiopathic hypersomnia and the smooth transition to low sodium oxybate in patients with narcolepsy.
Prophylactic Lumbar Drainage Following Aneurysmal Subarachnoid Hemorrhage Shows Additional Benefits
June 27th 2023At 6 months, a larger proportion of patients on standard of care experienced unfavorable outcomes, as demonstrated by modified Rankin Scale scores greater than 3, in comparison with lumbar drainage.
Biohaven Submits New Drug Application for Troriluzole as Spinocerebellar Ataxia Type 3 Therapy
June 25th 2023In a phase 3 study, a subgroup of patients with spinocerebellar ataxia treated with troriluzole demonstrated a numerical treatment benefit relative to placebo on the primary end point of change in f-SARA scores.
Pegcetacoplan to be Discontinued in ALS Following Disappointing Phase 2 Results
June 24th 2023In a trial of 250 adults with sporadic ALS, pegcetacoplan failed to meet its primary end point of change in Combined Assessment of Function and Survival rank scores relative to placebo after a 52-week stretch.